Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

$Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis$

News Daily News

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

Todd Neale

August 13, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2025

Shelley Wood

January 31, 2025

News Daily News

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Michael O'Riordan

January 03, 2025

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

L.A. McKeown

November 26, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

Shelley Wood

April 01, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Conference News TCT 2023

Intermittent Coronary Sinus Occlusion Fails to Cut Infarct Size in STEMI

Yael L. Maxwell

November 06, 2023

News Industry News

Neovasc Provides Further Update on Reducer™ Program for Treatment of Refractory Angina

July 16, 2019

News Industry News

Neovasc Announces Treatment of 1,000th Refractory Angina Patient with Neovasc Reducer™

May 06, 2019

News Industry News

Neovasc Announces Peer Reviewed Publication in the International Journal of Cardiology Demonstrating that the Neovasc Reducer™ Improves Diastolic Function in patients suffering from severe angina

April 17, 2019

$A Quarter of ‘No Option’ Patients With Refractory Angina End Up Receiving Revascularization Within 2 Years$

News Daily News

A Quarter of ‘No Option’ Patients With Refractory Angina End Up Receiving Revascularization Within 2 Years

Yael L. Maxwell

August 10, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2018

Caitlin E. Cox

April 30, 2018

$Positive Real-World Results for Coronary Sinus Reducer in Patients With Refractory Angina$

News Daily News

Positive Real-World Results for Coronary Sinus Reducer in Patients With Refractory Angina

Todd Neale

April 16, 2018

News Daily News

Narrowing Coronary Sinus May Provide Relief From Refractory Angina

Todd Neale

February 03, 2015

News Industry News

Neovasc Reducer™ Featured in Live Case Session at TCT 2014 Scientific Symposium

September 15, 2014

News Daily News

Add-on Cilostazol Reduces Restenosis in High-Risk Patients Receiving DES

August 08, 2013

News Industry News

Neovasc's Tiara™ transcatheter mitral valve selected as a best new device concept at TCT 2012 Scientific Symposium

October 23, 2012

Advertisement

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

TCTMD’s Top 10 Most Popular Stories for January 2025

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

November 2024 Dispatch for the CV Team

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

What’s Going to Be Hot at ACC 2024

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Intermittent Coronary Sinus Occlusion Fails to Cut Infarct Size in STEMI

Neovasc Provides Further Update on Reducer™ Program for Treatment of Refractory Angina

Neovasc Announces Treatment of 1,000th Refractory Angina Patient with Neovasc Reducer™

Neovasc Announces Peer Reviewed Publication in the International Journal of Cardiology Demonstrating that the Neovasc Reducer™ Improves Diastolic Function in patients suffering from severe angina

A Quarter of ‘No Option’ Patients With Refractory Angina End Up Receiving Revascularization Within 2 Years

TCTMD’s Top 10 Most Popular Stories for April 2018

Positive Real-World Results for Coronary Sinus Reducer in Patients With Refractory Angina

Narrowing Coronary Sinus May Provide Relief From Refractory Angina

Neovasc Reducer™ Featured in Live Case Session at TCT 2014 Scientific Symposium

Add-on Cilostazol Reduces Restenosis in High-Risk Patients Receiving DES

Neovasc's Tiara™ transcatheter mitral valve selected as a best new device concept at TCT 2012 Scientific Symposium

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content